Reasons to Retain Hims & Hers Stock in Your Portfolio for Now

Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating.